

# COLDA 2022

CONFERENCE ON  
LIVER DISEASE  
IN AFRICA



SOUTH AFRICA | 29 SEP - 1 OCT

**BILINGUAL - ENGLISH/FRENCH - LIVE TRANSLATION**



## Program Book

**ame** academic  
medical education

 **SHARE** | global health

[AcademicMedicalEducation.com](https://AcademicMedicalEducation.com)





|   |    |
|---|----|
| <b>Welcome</b>                                | 5  |
| <b>Organizing Committee</b>                   | 6  |
| <b>Scientific Committee &amp; Onsite Team</b> | 7  |
| <b>Practical Information</b>                  | 8  |
| <b>Program</b>                                | 10 |
| <b>Faculty</b>                                | 17 |
| <b>Acknowledgments</b>                        | 34 |







We are pleased to welcome you to the **5th Conference on Liver Disease in Africa (COLDA)** - to be held in person in Cape Town after 2 years of virtual meetings!

COLDA is endorsed by AASLD and EASL. We thank both of these societies for their ongoing support in empowering African healthcare professionals to diagnose, prevent, treat, and achieve a cure for all liver diseases.

We have developed an exciting academic program full of both local and international speakers, with a strong emphasis on science within Africa. There is ample time to network with old and new colleagues.

Our Faculty, invited speakers, and abstract presenters representing Africa and the International Hepatology community will address the challenges and progress achieved in addressing liver disease, particularly the elimination of viral hepatitis in Africa. The role of patient advocacy in driving viral hepatitis elimination programs is recognized, and we look forward to active interaction with many of the NGO's and community organizations involved in the support, education and linkage to care of individuals with viral hepatitis. There will a capacity building session on the role of point-of-care Liver Ultrasound in the management of liver diseases. You will also have the opportunity to personally interact with Rob Brierley, Editor-in-Chief of The Lancet Gastroenterology & Hepatology on how to prepare your manuscript for submission.

We hope that this conference will continue to act as a catalyst for translating science into clinical practice while promoting medical education in the field of hepatology and setting up active collaborations throughout the African region.

We look forward to sharing this exciting COLDA 2022 program and meeting you all in person in Cape Town.

## Program Chairs



**Mark Nelson  
MD, FRCP**

Chelsea and  
Westminster Hospital  
United Kingdom



**Manal El-Sayed  
MD, PhD**

Ain Shams University,  
Egypt



Local Chair

**Wendy Spearman  
MBChB, FCP, FRCP,  
MMed, PhD**

University of Cape Town,  
South Africa

**Disclaimer:** This conference aims to offer participants the opportunity to share information. Academic Medical Education cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this conference. Academic Medical Education disclaim all liability for injuries or losses of whatever nature incurred by individuals attending the conference.

## Organizing Committee



**Manal El-Sayed**  
**MD, PhD**  
Ain Shams University,  
Egypt



**Mark Nelson**  
**MA, MBBS, FRCP**  
Chelsea and Westminster  
Hospital / Imperial College  
Medical School,  
United Kingdom



**Bisi Bright**  
**B.Pharm(Hons), MPH,  
FPCPharm, FPSN,  
C.Psych**  
LiveWell Initiative (LWI),  
Nigeria



**Hailemichael Desalegn  
Mekonnen**  
**MD, PhD**  
St. Paul's Hospital Millennium  
Medical College,  
Ethiopia



**Geoffrey Dusheiko**  
**MBBS, FCP(SA) FRCS**  
Kings College Hospital,  
United Kingdom



**Anna Kramvis**  
**BSc Hons, PhD**  
Hepatitis Virus Diversity  
Research Unit / ICE-HBV,  
South Africa



**Jeffrey V. Lazarus**  
**PhD, MIH, MA**  
Barcelona Institute for Global  
Health (ISGlobal),  
Spain



**Olufunmilayo Lesi**  
**MD, MBA, FMCP**  
World Health Organization,  
Switzerland



**Casimir Manzengo**  
**MD, MPH**  
World Health Organization,  
Gabon



**Mark Sonderup**  
**B Pharm, MBChB,  
FCP(SA), MMed**  
University of Cape Town,  
South Africa



**Wendy Spearman**  
**MBChB, FCP, FRCP,  
MMed, PhD**  
University of Cape Town,  
South Africa



**John Ward, MD**  
Coalition for Global Hepatitis  
Elimination, Task Force for  
Global Health / Rollins School  
of Public Health, Emory  
University,  
United States



## Scientific Committee

|   |   |
|---|---|
| <b>Mary Afihene, MBChB, FWACP</b>             | Kwame Nkrumah University, Ghana   |
| <b>Kosh Agarwal, MD</b>                       | King's College Hospital, United Kingdom   |
| <b>Nabil Debzi, MD</b>                        | Algerian Society of Hepatogastroenterology and Endoscopy / Mustapha Hospital Algiers, Algeria |
| <b>Alice Guingané, MD, MPH</b>                | Bogodogo University Hospital Center / University of Montpellier, Burkina Faso / France        |
| <b>Kenneth Kabagambe</b>                      | National Organization for People Living with Hepatitis B, Uganda                              |
| <b>Emmanuel Musabeyezu, MD, FCP</b>           | King Faisal Hospital, Rwanda  |
| <b>Yvonne Nartey, MBChB, MSc, MPhil</b>       | Cape Coast Teaching Hospital, Ghana   |
| <b>Gibril Ndow, MD</b>                        | Imperial College London / London School of Hygiene & Tropical Medicine, The Gambia            |
| <b>John Rwegasha, MBChB, M.MED, FRCP, MSc</b> | Muhimbili National Hospital, Tanzania   |
| <b>Edford Sinkala, MD, PhD</b>                | University Teaching Hospital / University of Zambia, Zambia                                   |
| <b>Sonjelle Shilton, MPH</b>                  | Foundation for Innovative New Diagnostics (FIND), Switzerland                                 |
| <b>Elijah Songok, MD, PhD</b>                 | Kenya Medical Research Institute, Kenya   |
| <b>Christian Tzeuton, MD</b>                  | Douala Medical School / Société Camerounaise de Gastro-Enterologie, Cameroon                  |

## Onsite Team



**Karin Siebelt**  
Senior Project Manager  
[Karin.Siebelt@amededu.com](mailto:Karin.Siebelt@amededu.com)



**Rikke Puggaard-Rode**  
Senior Project Manager  
[Rikke.Rode@amededu.com](mailto:Rikke.Rode@amededu.com)



**Magda Sevlidou**  
Project Coordinator  
[magda.sevlidou@amededu.com](mailto:magda.sevlidou@amededu.com)

## Abstracts

Accepted abstracts are published in **Reviews in Antiviral Therapy & Infectious Diseases, Volume 2022\_9**.

## Accreditation

COLDA 2022 has been accredited by the University of Pretoria with **18 CEUs/points** in total. You are eligible to receive the points upon attending the full program and completing the post-conference survey.

If you are a presenter, please reach out to the conference secretariat as you may be eligible for additional point(s).

## Badge Policy

All registered delegates are provided with a conference badge. Admission to all events is restricted to registered delegates and official guests wearing their name badges. Please wear your badge at all times to ensure admission to the conference sessions. 25 EUR will be charged for replacing a lost badge.

## Certificate of Attendance

Certificates of attendance will be sent by e-mail in the week following the conference (after completion of the post-conference survey).

## Code of Conduct

All individuals are required to observe our Code of Conduct. We cannot tolerate any form of discrimination, harassment, disrespect, or the marginalization of those involved in our programs. Please report any incidents to AME via [info@amededu.com](mailto:info@amededu.com) or to one of our onsite personnel. Any participant who is found to have exhibited any inappropriate conduct or behavior against others may be removed from the program.

## Conference Secretariat

The conference secretariat is located at the registration desk in the pre-function area of the conference room. It is open throughout the conference to address all your questions concerning logistics.

## COVID-19 Measures

Please always follow the rules and regulations of the host country and the venue.

### Face Masks

Attendees are required to wear a face mask in order to enter the conference venue. The face mask must be worn during the entire length of the conference. Wearing a face mask will not be mandatory in the areas that are designated for the consumption of food and beverages.

### Hand Sanitizer

Multiple hand sanitizer stations will be set up throughout the conference venue. Please make sure to use them regularly.

## Feedback

Your feedback is very valuable to us as it allows us to continue to improve future editions of COLDA. Please complete the feedback forms that are distributed via email at the end of each conference day. Your feedback is much appreciated – we will use it to improve the program in 2023.

## Group Picture

On Thursday, September 29, prior to the welcome reception, we will take a group picture. Instructions will be provided in the session before the photo shoot. Please follow directions from the conference organisers to make this run as smoothly as possible.

## Posters

Posters are displayed in the Piazza on the ground floor together with the exhibition space. Please seek out the posters during refreshment breaks and lunch breaks. All poster presenters are asked to be at their posters during the poster viewing session so that you can discuss their work with them.

## Presentations and Webcasts

The webcast and PDF presentations will be made accessible on demand via the conference website ([www.AcademicMedicalEducation.com](http://www.AcademicMedicalEducation.com)) after three weeks

## Social Program

*Thursday September 29 – 17:30* | The welcome reception, market place, and poster viewing are scheduled after the last plenary session on the first day of COLDA 2022.

## Presenters

Presenters are requested to submit their presentation as early as possible, latest in the break prior to their session. Our technicians will be available for you at the technician table in the conference room.

## Social Media

We encourage you to post news about COLDA to your social media accounts and tweet about COLDA as often as you like during the conference. You can post your own tweet to your followers using the hashtag #COLDA.

## WiFi

Free WiFi is available throughout the conference venue. To connect to the WiFi, select the **COLDA2022** network and enter the password: **COLDA2022**





# Program

## Thursday, 29 September

Times are in South African Standard Time

|  |   |  |   |
|--|---|--|---|
| 08:00  | Registration Open - Early Morning Tea   |  |   |
| <b>Parallel Capacity Building Sessions</b>   |   |  |   |
| 08:30  | <b>Ultrasonography Point-Of-Care</b>  | <b>The Role of Community Groups in Screening and Linkage to Care</b> | <b>Ask the Editor - Preparing a Manuscript for Submission</b> |
| <b>Opening of the Conference - Call for Action</b><br><i>Chairs: Wendy Spearman &amp; Manal El-Sayed</i>                                     |   |  |   |
| 10:30  | <b>Welcome Words</b><br><b>Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD</b><br>University of Cape Town, South Africa<br><b>Manal El-Sayed, MD, PhD</b><br>Ain Shams University, Egypt<br><b>Mark Nelson, MD, FRCP</b><br>Chelsea and Westminster Hospital, United Kingdom<br><b>Margareth Ndomondo-Sigonda, PhD</b><br>Head of the Health Programme for AUDA-NEPAD (African Union Development Agency - New Partnership for Africa's Development) |  |   |
| 10:45  | <b>Call for Action - "We Need to Address the Challenges - Now" - The South African Experience</b><br><b>Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD</b><br>University of Cape Town, South Africa  |  |   |
| 11:00  | <b>Call for Action - "We Need (HQ) Data - To Plan Services"</b><br><b>Olufunmilayo Lesi, MD, MBA, FMCP</b><br>World Health Organization, Switzerland  |  |   |
| 11:15  | <b>Call for Action - "We Need Solutions"</b><br><b>Agnes Binagwaho, MD, M(Ped), PhD</b><br>University of Global Health Equity, Rwanda   |  |   |
| 11:30  | <b>Call for Action - "Call for Action - "We Need Testing and Treatment - NOW""</b><br><b>Bisi Bright, B.Pharm(Hons), MPH, FPCPharm, FPSN, C.Psych</b><br>LiveWell Initiative (LWI), Nigeria   |  |   |
| 11:45  | <b>Discussion</b>   |  |   |
| 12:10  | Lunch   |  |   |
| <b>Session 1: Hepatitis Elimination Part 1 - Screening / Testing / Monitoring</b><br><i>Chairs: Philippa Easterbrook &amp; Mark Sonderup</i> |   |  |   |
| 13:10  | <b>From Pandemic Response to Pandemic Recovery - Opportunities for Viral Hepatitis Elimination</b><br><b>John Ward, MD</b><br>Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States   |  |   |
| 13:35  | <b>Blood Safety &amp; Surveillance</b><br><b>Yuyun S. Maryuningsih, MD, PhD</b><br>World Health Organization, Switzerland   |  |   |
| 13:55  | <b>Discussion</b>   |  |   |



**14:15 Symposium 1 - Abbott: HBV Testing as Part of Triple Elimination Strategy - What Is Holding Us Back?**

*Chair: John Ward*

**Global Burden of Disease: Elimination Of Hepatitis B & Current Challenges**

**John Ward, MD**

Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States

**Approach to HBV Testing in the Fight for Hepatitis Elimination - Experience Sharing from Rwanda**

**Janvier Serumondo, MD, MSc, MPH**

Approach to HBV Testing in the Fight for Hepatitis Elimination - Experience Sharing from Rwanda

**Additional Panelists**

**Nabil Debzi, MD**

Algerian Society of Hepatogastroenterology and Endoscopy / Mustapha Hospital Algiers, Algeria

**Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD**

University of Cape Town, South Africa

**Facilitators**

**Lindsey Hiebert**

Coalition for Global Hepatitis Elimination, Task Force for Global Health, United States

**Evans Mathebula, MSc, PhD**

Medical Scientific Affairs Manager for Africa, South Africa, Abbott

15:15 Tea Break

**Session 2: Hepatitis Elimination Part 2**

*Chairs: John Ward & Neliswa Gogela*

**15:45 Vertical Transmission, Maternal Care, and Family Care**

**Manal El-Sayed, MD, PhD**

Ain Shams University, Egypt

16:10 **Q & A**

**16:15 Modelling Elimination Strategies in Africa**

**Shevanthi Nayagam, MBBS, MRCP, PhD**

Imperial College, United Kingdom

16:40 **Q & A**

**16:45 Panel Discussion: Effectiveness of HepB birth Dose Vaccination**

17:30 Welcome Reception & Poster Viewing & Market Place

## Friday, September 30

Times are in South African Standard Time

### Symposium 2 - Cepheid: Leveraging the GeneXpert for Hepatitis Elimination from Zambia and Nigeria

Chair: Andrew Schiebe

- 08:30 **Introduction**  
**Andrew Scheibe, MBChB, Dip HIV Man, MPH**  
 University of Pretoria, South Africa
- 08:35 **Expanding Access to HCV Viral Load Testing Outside Centralized Settings in Nigeria**  
**Chukwuemeka Agwuocha, PharmB**  
 Clinton Health Access Initiative, Nigeria
- 08:45 **Hepatitis B DNA Non-Suppression During Long-Term Treatment of HIV/HBV Coinfection in Zambia**  
**Michael Vinikoor, BSc, MD**  
 University of Zambia, Zambia / Infectious Diseases University of Alabama Health System, United States
- 08:55 **Q&A**

### Session 3: Integration Hepatitis Care into other Health Care Services

Chairs: Mark Nelson & Elijah Songok

- 09:00 **Integrated Decentralized Guidelines for Care – WHO Guidelines**  
**Philippa Easterbrook, MD, FRCP, MPH, DTM&H**  
 World Health Organization, Switzerland
- 09:20 **Can Integration Reduce Stigma? / Lessons Learned from HIV**  
**Danjuma Adda, MPH, FIMS, Dip-IMS**  
 World Hepatitis Alliance (WHA), Nigeria
- 09:40 **Cost-Effectiveness of the Integration / Country Experience - Rwanda**  
**Janvier Serumondo, MD, MSc**  
 Rwanda Biomedical Centre, Rwanda

### Abstract - Driven Presentation:

- 10:00 **Integrating hepatitis B into HIV programs in sub-Saharan Africa: pilot clinic experience in Zambia** Wamundila Kawana #1

### 10:10 Discussion

10:30 Tea Break

### Session 4: Clinical Management of Hepatitis - Oral Abstract Presentations

Chairs: Geoffrey Dusheiko & Nabil Debzi

- 11:00 **5-Year Results of a Treatment Program for Chronic Hepatitis B in Ethiopia** Hailemichael Desalegn Mekonnen #2
- 11:10 **Hepatitis B Birth Dose Coverage Remains Dramatically Low in the Gambia and Has Been Disrupted by the COVID-19 Pandemic** Gibril Ndow #3
- 11:20 **Hepatitis B Infection Prevalence, Genotype Distribution, and Knowledge of Mother-To-Child Transmission Among Antenatal Care Attendees in Yako, Rural Burkina Faso** Serge Ouoba #4
- 11:30 **Hepatitis Delta Virus Co/Super-Infection Surveillance among Clinicians: An Often-Neglected Practice in Nigeria** Ijeoma lfeorah #5
- 11:40 **Séroprévalence du virus de l'hépatite D (VHD) chez des patients porteurs chroniques de l'antigène HBs du virus de l'hépatite B (VHB) à Abidjan de janvier 2017 à Aout 2021 (COTE-D'IVOIRE)** Jean-Louis Philippe N'Din #6
- 11:50 **Discussion**



### Symposium 3 - Gilead: HCV: A Silent Epidemic Which Should Not Remain Silent

Chair: Neliswa Gogela

- 12:00 **Introductions**  
**Neliswa Gogela, MD**  
Groote Schuur Hospital / the University of Cape Town, South Africa
- 12:05 **Introduction to Gilead Sciences**  
**Michael Reid, MBChB, MScMedSci, PGDip Pharm Med**  
Gilead Sciences, Sub-Saharan Africa
- 12:10 **'More common than you think...'**  
**Bilal Bobat, MBChB, FCP**  
Wits Donald Gordon Medical Centre, South Africa
- 12:25 **Approach to Key Populations**  
**Andrew Scheibe, MBChB, Dip HIV Man, MPH**  
University of Pretoria, South Africa
- 12:40 **Panel Discussion and Q and A**

13:00 Lunch

### Session 5: EASL - Non-invasive Markers for Diagnosis of Liver Disease

Chair: Aleksander Krag

- 14:00 **Introduction**  
**Aleksander Krag, PhD, MBA**  
Odense University Hospital / EASL, Denmark
- 14:05 **Role of Non Invasive Markers for Identification of Advanced Fibrosis in Patients at Risk of Liver Disease**  
**Laurent Castera, MD, PhD**  
University of Paris-VII, France
- 14:25 **Non Invasive Markers in Viral Hepatitis and Alcoholic Liver Disease**  
**Aleksander Krag, PhD, MBA**  
Odense University Hospital / EASL, Denmark
- 14:45 **Q&A**

### Session 6: Clinical Management of Liver Disease - Oral Abstract Presentations

Chairs: Gibril Ndow & Edford Sinkala

- |       |  |                        |     |
|-------|--|------------------------|-----|
| 15:00 | <b>Hepatitis C Laboratory Data Analysis on Patients Seeking Medical Attention in the Public Health Sector, South Africa, 2017-2021</b>   | Morubula J Manamela    | #7  |
| 15:10 | <b>Performance-Based Approach to Accelerate Hepatitis C Elimination in Rwanda</b>  | Ephrem Daniel Sheferaw | #8  |
| 15:20 | <b>Prevalence and Mortality Trends of Hepatitis B and Hepatitis C Infection in Sub-Saharan Africa: A Systematic Analysis for the Global Burden of Disease Study 2020</b>           | Hannah Han             | #9  |
| 15:27 | <b>Trends of Hepatitis-Associated Cirrhosis and Liver Cancer in Sub-Saharan Africa: A Systematic Analysis of the Global Burden of Diseases and Injuries Study 2020 (Gbd 2020)</b>  | Hannah Han             | #10 |
| 15:35 | <b>An Assessment of Metabolic Syndrome and Cardiovascular Risk Scores Among Patients With Non-alcoholic Fatty Liver Disease (NAFLD) at the Cape Coast Teaching Hospital, Ghana</b> | Ansumana Bockarie      | #11 |

15:45 **Discussion**

15:55 Tea Break

## Session 7: Clinical Management of Viral Hepatitis

*Chairs: Anna Kramvis & Manal El-Sayed*

- 16:25 **Publishing in High-Impact Journals: Insights from an Editor**  
**Rob Brierley**  
The Lancet Gastroenterology & Hepatology, United Kingdom
- 16:50 **State-of-the-Art Lecture: HBV Cure**  
**Geoffrey Dusheiko, MBBS, FCP(SA) FRCS**  
Kings College Hospital, United Kingdom
- 17:15 **Panel Discussion: Clinical Trials in Africa - Challenges & Barriers**  
**Philippa Easterbrook, MD, FRCP, MPH, DTM&H**  
World Health Organization, Switzerland  
**Michael Reid, MBChB, MScMedSci, PGDip Pharm Med**  
Gilead, South Africa

## Session 8: Project ECHO

*Chairs: Wendy Spearman & Mark Sonderup*

- 17:40 **Introduction**  
**Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD**  
University of Cape Town, South Africa
- 17:45 **HBV Case - When is it NOT Acute Hepatitis B?**  
**Sandy Mosenye, Bsc( Med Science), MBChB, MMed, FCP(SA)**  
University of Capetown, South Africa  
**Panelist**  
**Stephen Korsman, MBChB, FCPATH(SA)Viro, MMed**  
University of Capetown, South Africa
- 18:00 **HCV Case - Understanding Patterns of Hepatitis C Transmission in a Rural Community**  
**Elizabeth Gatley, MBChB, FCP (SA)**  
University of Capetown, South Africa  
**Panelist**  
**Heidi Smuts, BSc (Hons), PhD**  
Groote Schuur Hospital, South Africa

## Saturday, October 1

*Times are in South African Standard Time*

## Session 9: AASLD - African Guidelines in HCC

*Chair: Lewis Roberts*

- 08:30 **Introduction**  
**Lewis R. Roberts, MBChB, PhD, FAASLD**  
University of Cape Town, South Africa
- 08:35 **Improving Early Detection/Diagnosis**  
**Nicole E. Rich, MD**  
UT Southwestern Medical Center, United States
- 08:50 **Early-Stage Disease**  
**Ashraf Omar, MD**  
Cairo University, Egypt
- 09:05 **Late-Stage Disease**  
**Ghassan K. Abou-Alfa, MD**  
Memorial Sloan Kettering Cancer Center, United States
- 09:20 **Panel Discussion & Close**



## Session 10: The Challenges of Hepatobiliary Surgeries in Sub-Saharan Africa

Chair: Marc Bernon & Ashraf Omar

09:30 **Liver Surgery**  
**Eduard Jonas, MB, ChB, MMed, FCS, PhD**  
University of Cape Town / Groote Schuur Hospital, South Africa

09:55 **Liver Transplantation Egypt/SA Model - Cote d'Ivoire**

**Amr Abdelaal, MD, FACS**

Ain Shams University, Egypt

**Elie Keli, MD**

University Hospital of Treichville, Côte d'Ivoire

### Abstract - Driven Presentation:

10:20 **Long-Term Follow-up in Liver Transplant Recipients: First Local Experience** Nabil Debzi #12

10:30 **Roundtable Discussion**

**Eduard Jonas, MB, ChB, MMed, FCS, PhD**

University of Cape Town / Groote Schuur Hospital, South Africa

**Amr Abdelaal, MD, FACS**

Ain Shams University, Egypt

**Elie Keli, MD**

University Hospital of Treichville, Côte d'Ivoire

**Abdelmounem Abdo, MD**

Ibn Sina Hospital, Sudan

**Nabil Debzi, MD**

Algerian Society of Hepatogastroenterology and Endoscopy / Mustapha Hospital Algiers, Algeria

10:45 Tea Break

11:15 **Best of Posters**

Chair: Mark Nelson

## Session 11: Management of End Stage Liver Disease - Real Life Challenges

Chairs: Bilal Bobat & Hailemichael Desalegn Mekonnen

11:40 **Cirrhosis Management in Resource Constraint Environments**

**Mark Sonderup, B Pharm, MBChB, FCP(SA), Mmed**

University of Cape Town, South Africa

12:10 **Panel Discussion - Best Practice**

12:30 **Closure of the Conference**

**Wendy Spearman, MBChB, FCP, FRCP, MMed, PhD**

University of Cape Town, South Africa

**Manal El-Sayed, MD, PhD**

Ain Shams University, Egypt

**Mark Nelson, MD, FRCP**

Chelsea and Westminster Hospital, United Kingdom







## Invited Speaker

**Amr Abdelaal,  
MD, FACS**

Ain Shams University,  
Egypt

Graduated from Ain Shams University, Cairo (1993). One year of internship (1994) & 3 years of residency in general Surgery department, Ain Shams University. Master degree (1997) & MD degree (2000) in General Surgery, Ain Shams University. Now, Professor of HBP surgery & LTx in Ain Shams University.

Trained in HPB Surgery & Liver Transplantation in Hopital Edouard Herriot- Lyon, France as a resident (2001 2002) and Fellow (2005- 2008). Currently, Head of the HPB unit & director of LDLTx program in Air Force Specialized Hospital & Nasser institute for treatment & research. Founder and first President of the (ELTS) Egyptian Liver Transplantation Society. Member of the Egyptian Supreme Council of Organ Transplantation. Councilor at large & now Secretary of the Pan Arab Liver Transplant Society (PALTS). Fellow of the American college of Surgeons (FACS) and Founder of the MENA chapter of IHPBA. Founder of the LDLTx unit in Saudi German Hospital in Jeddah – Kingdom of Saudi Arabia, from 2016. Founder of the LDLTx unit in Abidjan – Cote d’ Ivoire, from 2021 through collaboration with Triche ville university and the World Health Organization.

No potential conflict of interest to report



## Panelist

**Abdelmounem Abdo,  
MD**

Ibn Sina Hospital,  
Sudan

Dr Abdelmounem E Abdo is consultant physician and Gastroenterologist working at Ibsina gastroenterology Centre, Khartoum Sudan. Interventional gastroenterologist  
Field of interest is hepatitis, HCC, portal hypertension ERCP, Small bowel endoscopy.

He is the Director of the National Centre for Gastrointestinal and liver disease. Director of world gastroenterology Khartoum training Centre.

He is the Vice President of the Sudanese society of gastroenterology, president elect of the African and Middle East association of gastroenterology, Secretary General of Panarab Association of gastroenterology.

Dr Abdelmounem is leading through he National Centre for gastrointestinal liver disease in collaboration with department of Infection disease control FMOH and WHO great efforts in hepatitis strategic eradication program. Dr Abdelmounem is leading program of establishment of hepatobiliary , pancreatic and liver transplantation Centre in Khartoum, which will deliver the service and training in Sudan and neighbouring African countries.

This program supported by Sudan federal ministry of health and Sudanese business man Mr Mohamed salih Idris donated 2.5 million dollars for building the center.

## Potential conflict of interest

No Information Received



**Invited Speaker**  
**Danjuma Adda,**  
**MPH, FIMS, Dip-IMS**

World Hepatitis Alliance  
(WHA),  
Nigeria

Danjuma K. Adda is a Nigerian prince and accomplished Public health expert on a mission to raise awareness about Hepatitis. Danjuma was infected with Hep B while in clinical rotations and then lost his own mother to the disease several years later. Even though Hepatitis kills more people per year than HIV/AIDS, it receives just a fraction of the global health funding.

Danjuma is a leading voice for Hepatitis patients in Nigeria and uses his platform to advocate for the most vulnerable populations across Africa. He wants to change the narrative about Hepatitis and raise awareness about the deadliness of the disease.

Danjuma is a native of Taraba state, Nigeria. He is married with four kids. He has a background in microbiology/virology, and an MPH, with over 15 years-experience in public health and advocacy.

Danjuma is the current President elect of the World Hepatitis Alliance (WHA), the first African to hold that position.

**Potential conflict of interest**

Pfizer, ViiV, Gilead



**Session Chair**  
**Marc Bernon,**  
**MBBCh**

University of Cape Town,  
South Africa

Dr. Marc Bernon is Hepatobiliary and pancreatic surgeon. He is currently a consultant and senior lecturer in the UCT Hepato-pancreatico-biliary (HPB) surgical unit.

Dr. Bernon has been involved in setting up a number of disease specific registries at Groote Schuur Hospital that are aimed at improving the outcomes of patients with hepatocellular carcinoma, pancreatic cancer and portal hypertension.

The UCT HPB surgical unit is one of the few units on the continent that is able to offer all the potentially curative treatment modalities for hepatocellular carcinoma and is involved in a number of outreach activities to increase awareness of hepatocellular carcinoma.

**Potential conflict of interest**

No Information Received



**Invited Speaker**  
**Agnes Binagwaho,**  
**MD, M(Ped), PHD**

University of Global Health  
Equity,  
Rwanda

Professor Agnes Binagwaho, MD, M(Ped), PHD currently resides in Rwanda. She is the Vice Chancellor and co-founder of the University of Global Health Equity (UGHE) (in 2015), an initiative of Partners In Health based in Rwanda which focuses on changing how health care is delivered around the world by training global health professionals who strive to deliver more equitable, quality health services for all.

She is a Rwandan pediatrician who returned to Rwanda in 1996, two years after the 1994 Genocide Against the Tutsi. Previously, she has provided clinical care in the public sector and has served the Rwandan health sector (1996-2016) in high-level government positions, first as the Executive Secretary of Rwanda's National AIDS Control Commission, then as Permanent Secretary of the Ministry of Health, and lastly as Minister of Health for five years.

She is a Professor of Pediatrics at UGHE, a Senior Lecturer in the Department of Global Health and Social Medicine at Harvard Medical School, and an Adjunct Clinical Professor of Pediatrics at Dartmouth's Geisel School of Medicine.

She is member of multiple editorial, advisory and directors' boards, including the Think20 (T20), the Rockefeller Foundation, the African Europe Foundation and the African Union Commission on COVID-19 Response. Professor Binagwaho is a member of the U.S. National Academy of Medicine and the World Academy of Sciences, and a fellow of the African Academy of Sciences. She has published over 230 peer-reviewed articles and was named among the 100 Most Influential African Women for 2020 and 2021 and is a recipient of the L'Oréal-UNESCO Award for Women in Science.

No potential conflict of interest to report



**Session Chair**  
**Bilal Bobat,**  
**MBChB, FCP**

Wits Donald Gordon Medical  
Centre,  
South Africa

Bilal Bobat is based at the Wits Donald Gordon Medical Centre Liver Unit where he is a transplant hepatologist.

His interests include Autoimmune liver disease and specifically Primary Sclerosing Cholangitis.

He is an honorary lecturer at the University of Witwatersrand in Johannesburg and serves on regional and international Gastroenterology and Hepatology committees.

**Potential conflict of interest**

No Information Received



## Invited Speaker

### **Rob Brierley,**

The Lancet Gastroenterology & Hepatology,  
United Kingdom

Rob Brierley is Editor-in-Chief of The Lancet Gastroenterology & Hepatology. Rob studied molecular and cellular biochemistry and clinical pharmacology at the University of Oxford, and clinical oncology at the University of Birmingham. Rob has worked in the publishing industry since graduation, first as a technical editor for the Journal of Molecular Biology, before working on a series of viral hepatitis textbooks for a book publishers.

Rob joined The Lancet Group in 2004, first at The Lancet Infectious Diseases and The Lancet, before joining The Lancet Oncology as Senior Editor in 2008 and then Deputy Editor in 2012. The Lancet Gastroenterology & Hepatology launched in 2016.

Rob's interests include gastrointestinal and hepatobiliary cancers, viral hepatitis, and inflammatory bowel diseases.

#### Potential conflict of interest

Elsevier Ltd



## Organizing Committee

### **Bisi Bright,**

**B.Pharm(Hons), MPH, FPC-Pharm, FPSN, C.Psych**  
LiveWell Initiative (LWI),  
Nigeria

Bisi Bright is a Consultant Clinical Pharmacist, Lecturer, and Public Health Manager. She is 1st Vice Chairman and CEO of LiveWell Initiative LWI, a self-sustaining nonprofit healthcare social enterprise.

Appointed a Practicum Preceptor for MPH and DrPH candidates at the prestigious Harvard T H Chan School of Public Health in Boston USA, she sat on the Faculty of the Economist Conferences' Healthcare in Africa; and also served on the Africa Regional Steering Committee of the IAPO (International Alliance for Patients' Organisations) from 2009-2012.

Bisi Bright was the first black African Honoree to be recognized as GLOBAL CHANGEMAKER2017 IN HEPATITIS C, by the EIU (Economist Intelligence Unit) (please see link at <http://bit.ly/2xa665o>), and she received a Commendation Letter from the Presidency at Aso Rock Villa, Nigeria, for her work in Hepatitis.

Bisi has written well over 100 published articles, some of which are in peer-reviewed journals, and is a Doctoral Thesis Supervisor at the University of Helsinki, Finland. She is a two-time International Award winner of the IATDM/CT and a winner of other Awards - local and international.

Since the advent of COVID-19 her organisation LWI has been busy researching into the use of 4-Aminoquinolines in COVID-19 Response, and has obtained Research and Ethics Committee Approval. The organisation, along with its subsidiary Women In Hepatitis Africa, embarked on PMTCT Project in 2019 as a commemoration for World Hepatitis Day, by adopting a Policy to screen every pregnant woman for viral hepatitis. The advocacy for Birth Dose vaccination against hepatitis B, is a core project which Bisi has vigorously pursued and embraced, with great passion.

Bisi serves as a Board Member of the International Alliance of Patients Organisations IAPO - a member of the British Charities Trust; and as a Patient Expert, she is passionate about the Patient Cause.

#### Potential conflict of interest

No Information Received



**Session Chair**

**Nabil Debzi,  
MD**

Algerian Society of Hepato-  
gastroenterology and Endos-  
copy / Mustapha Hospital  
Algiers, Algeria

Nabil Debzi is a professor of medicine, graduated from the Algiers faculty of medicine. Since 2015, he is the head of the hepatology department in Mustapha Bacha University Hospital of Algiers. The team he leads is particularly interested and involved in liver transplantation, vascular liver diseases (Budd Chiari Syndrome), viral hepatitis, and hepatocellular carcinoma.

He is the president of the Algerian Society of Hepatogastroenterology and Endoscopy and the past president of the Algerian Society of Organ Transplantation. Professor Nabil Debzi is also the coordinator of the National Viral Hepatitis Committee.

**Potential conflict of interest**

No Information Received



**Organizing Committee**

**Hailemichael  
Desalegn Mekonnen,  
MD, PhD**

St. Paul's Hospital Millennium  
Medical College,  
Ethiopia

Dr. Hailemichael Desalegn graduated from medical school and specialty in Internal Medicine at Jimma University, Ethiopia. He completed a fellowship program in Gastroenterology/Hepatology in 2014 at Addis Ababa University. In 2020, he has successfully defended his PhD with an outstanding performance at Aklilu Lemma Institute of Pathobiology (ALIPB) on Tropical and Infectious Disease (TRID). The main focus of his PhD work on Non-invasive markers of Liver Fibrosis and simplified treatment program for Hepatitis B virus in Sub-Saharan Africa. He is currently working as an Associate Professor and Consultant Gastroenterologist/Hepatologist in St. Paul's Hospital Millennium Medical College. He has established and is a Director of Sub-Saharan Africa Gastroenterology ECHO clinic.

Dr. Hailemichael has publications in reputable Journals and is actively involved in the fight against viral hepatitis elimination. As one of the few gastroenterologists in his country of more than 100 million individuals, he has a passion to translate research findings to improvements in the access and quality of care and simplified approach for hepatitis in resource limited settings.

He has built successful research collaborations addressing key questions in the area of viral hepatitis and hepatocellular carcinoma. Through collaboration, he has established one of the largest treatment cohorts for Hepatitis B in sub-Saharan Africa. Through this cohort, he has contributed key knowledge in the presentation, natural evolution, and treatment success for Hepatitis B in Ethiopia. He was also involved in simplified point of care tests for Hepatitis B and Hepatitis C viruses. Additionally, he led a study on hepatocellular carcinoma through an award from the International Liver Cancer Association.

**Potential conflict of interest**

No Information Received



## Organizing Committee

**Geoffrey Dusheiko,**  
MBBS, FCP(SA) FRCS

Kings College Hospital,  
United Kingdom

Geoffrey Dusheiko, FCP(SA) FRCS, is Emeritus Professor of Medicine at the Royal Free Hospital and University College London School of Medicine and Consultant Hepatologist at Kings College Hospital London, in London, UK.

After earning his MBBS degree from the University of Witwatersrand in Johannesburg, South Africa, Professor Dusheiko completed his internship at the Chris Hani Baragwanath Hospital in Johannesburg and his residency at Johannesburg Hospital. His fellowships were conducted at the Johannesburg Hospital Liver Unit and the National Institutes of Health, Maryland, and the University of Minnesota, USA.

Professor Dusheiko's research interests include the management and treatment of HCV and HBV and small hepatocellular carcinoma; he has a special interest in research on viral hepatitis, especially viral genotyping, applied molecular virology, the natural history of chronic viral hepatitis and antiviral therapies. A member of several organisations, including EASL, AASLD and IASL, Professor Dusheiko is also a Fellow of the Royal College of Physicians, the Royal College of Physicians of South Africa, and the Royal College of Physicians of Edinburgh. He previously served as Educational Councilor on the Governing Board of EASL for 4 years and was the recipient of the EASL Recognition Award in 2014. An advisor for the UK National Institute of Health and Care Excellence, Professor Dusheiko is an author of the World Health Organization's HBV guidelines and he was a Director of the Skipton Fund, a UK ex gratia payment scheme for patients infected with HCV through contaminated blood products. He served as interim Deputy Director of the Blood Safety, HIV, viral hepatitis and STI Division of Public Health England in 2019.

He is a co-editor of Alimentary Pharmacology and Therapeutics, and has previously served on editorial boards for the Journal of Viral Hepatitis, Hepatology, Best Practice & Research Clinical Gastroenterology, and Gut among others. Professor Dusheiko has authored or co-authored more than 500 articles in international peer-reviewed journals or books.

### Potential conflict of interest

No Information Received



## Invited Speaker

**Philippa Easterbrook,**  
MD, FRCP, MPH, DTM&H

World Health Organization,  
Switzerland

Philippa Easterbrook is Senior Scientist in the Global Hepatitis Programme, HIV department at the World Health Organisation Headquarters in Geneva. She is an HIV and infectious diseases physician and epidemiologist who has worked in the UK, United States and Sub-Saharan Africa.

At WHO, she has led the development and dissemination of global normative guidance for HIV as well as Hepatitis B and C testing and treatment, and in 2021 new guidance on criteria for country validation of elimination of viral hepatitis. She also provides technical guidance to national programmes worldwide on the implementation of hepatitis B and C testing and treatment scale-up programmes as part of a global elimination strategy.

For eleven years, she was Head of Department, Professor of HIV Medicine, and consultant physician in Infectious Diseases at King's College London, and also Head of Research at the Infectious Diseases Institute in Uganda.

Philippa has served as a Member of the UK Medical Research Council Infection and Immunity Committee, as vice-chair of the World Health Organization Guidelines Review Committee, and since 2021 on the WHO headquarters COVID Publications Review Committee.

Her HIV research has encompassed epidemiology, clinical trials, operational/implementation science and qualitative research, and laboratory-based studies.

No potential conflict of interest to report



### Conference Chair

**Manal El-Sayed,**  
MD, PhD

Ain Shams University,  
Egypt

Dr. Manal El-Sayed (Cairo, Egypt) is Professor of Pediatrics at Ain Shams University. She is the clinical director of the national HCV Pediatric treatment program and the director of the clinical research unit and co-supervisor of the viral hepatitis treatment center at Ain Shams University. Manal has worked with pediatric hematology and oncology teams at Ain Shams University, National Cancer Institute, and 57357 Children's Cancer Hospital since 1990.

Manal is a founding member of the Egyptian National Committee for Control of Viral Hepatitis (NCCVH) charged with planning and implementing the nationwide program for prevention and management of viral hepatitis since 2006. She contributed to the establishment of a nationwide network of 55 specialized liver centers that provided interferon therapy to 350,000 HCV-infected patients. Since 2014 when the NCCVH introduced the new direct-acting antiviral agents for HCV, more than 3 million patients have been treated. Manal collaborated on the development of the national action plan for prevention and control of viral hepatitis published in October 2014 with representatives from WHO, the U.S. Centers for Disease Control and Prevention (U.S. CDC), Pasteur Institute, and national stakeholders. In addition to co-supervising the nationwide mass screening program for adults and children reaching so far more than 56 million people.

Manal is also an active board member and secretary general of the Egyptian Liver Care Society, a non-governmental organization that offers financial assistance to patients receiving treatment for hepatitis or liver transplants. She has authored and co-authored numerous journal articles on hepatitis and liver diseases, and participated in the development of WHO's HBV, HCV and diagnostic guidelines. From 2011-2015, Manal was Vice Chair of WHO's Technical Advisory Group for Prevention and Control of Viral Hepatitis in Egypt. She is also a board member of the European Study of Liver Disease International Liver Foundation since January 2018. In addition to being an oversight committee member of the EndHep2030 initiative since the beginning of 2019.

#### Potential conflict of interest

No Information Received



### Session Chair

**Neliswa Gogela,**  
MD

Groote Schuur Hospital / the  
University of Cape Town,  
South Africa

Neliswa Gogela is a hepatologist and a specialist physician at Groote Schuur Hospital / the University of Cape Town, South Africa. She obtained her Masters of Philosophy, specializing in Advance Hepatology and Transplantation at the University of Cape Town in 2018, her thesis looked at the Prevalence of hepatitis C infection in men who have sex with men (MSM) in South Africa. During her fellowship training, she was awarded a grant by the Discovery Foundation which took her to Massachusetts General Hospital, a Harvard affiliate in Boston USA. This allowed her to advance her research career in viral hepatitis studies for a period of one year.

She prides herself in being the first black female hepatologist in the country, a specialty that has less than a handful of specialists in SA, and her passion and drive are mentoring and training future clinicians and specialists in the state hospital. Besides her demanding profession, she is the proud mother of 3 boys who provide balance and fulfillment in her busy career.

#### Potential conflict of interest

No Information Received



## Invited Speaker

**Eduard Jonas,**  
MB, ChB, MMed, FCS, PhD

University of Cape Town /  
Groote Schuur Hospital,  
South Africa

Eduard Jonas underwent his pre-graduate training at the University of Pretoria, South Africa obtaining a MBChB in 1985. He did his surgical training at the University of Stellenbosch, becoming a Fellow of the South African College of Surgeons in 1995 and obtaining a MMed in general surgery.

He served as consultant surgeon in the Upper Gastrointestinal Service of the Department of General Surgery at the University of Stellenbosch and Tygerberg hospital before taking up an endoscopy fellowship position at Karolinska University Hospital, Stockholm, Sweden in 1997 where he obtained a PhD. He previously held clinical positions in Karolinska Institute affiliated hospitals, including the Departments of Surgery at Danderyd Hospital and Karolinska University Hospital.

He is affiliated to the Karolinska Institute as Associate professor and since 2015 is Professor of Surgery and Head of the Surgical Gastroenterology Unit at the University of Cape Town and Groote Schuur Hospital.

No potential conflict of interest to report



## Invited Speaker

**Elie Keli,**  
MD

Treichville University Hospital,  
Cote d'Ivoire

Professor Elie Keli is an Associate Professor, Head of the Department of General, Digestive and Endocrine Surgery, Treichville University Hospital, Abidjan, Cote d'Ivoire. He qualified as a medical doctor in 1986 from the Felix Houphouet-Boigny University. After completing his internship he started his training as a general surgeon at Treichville University Hospital. This was followed by HPB surgery training at Laennec Hospital and Saint-Antoine Hospital in Paris, France where he developed an interest in liver transplant surgery. Between 2006 and 2016, as a visiting surgeon, he underwent training at the Thomas E. Starzl Transplantation Institute at the University of Pittsburgh. His academic appointments include an Assistant Professorship in 1998, followed by an Associate Professorship in 2004 at the Treichville University Hospital, Abidjan.

He held a professional appointment of head of the Department of General surgery at Hôpital Militaire d'Abidjan from 2000 to 2015.

He is also the Director of the General Surgery postgraduate training program at medical school the Felix Houphouet Boigny University.

Currently he is the president of Société Ivoirienne de Chirurgie Digestive.

He is a member of the International Hepato-Pancreato-biliary Association.

No potential conflict of interest to report





**Panelist**  
**Stephen Korsman,**  
MChB, FCPATH(SA)Viro,  
MMed  
University of Cape Town,  
South Africa

Stephen Korsman is a senior lecturer/consultant virologist at the Groote Schuur Complex of National Health Laboratory Service (NHLS) and the Division of Medical Virology, Department of Pathology, Faculty of Health Sciences at the University of Cape Town.

He obtained his medical degree from the University of Pretoria in 1999, his Fellowship of the College of Pathologists (Virology) of South Africa in 2005, and completed his dissertation for his Masters of Medicine (Virology) titled "Molecular Epidemiology of Mother-to-Child Transmission of HIV-1 in Children at Tygerberg Hospital" at Stellenbosch University in 2006.

His interests include undergraduate medical student teaching, molecular biology, virology in court, Hepatitis B, and Hepatitis E.

**Potential conflict of interest**

No Information Received



**Organizing Committee**  
**Anna Kramvis,**  
BSc Hons, PhD  
Hepatitis Virus Diversity  
Research Unit / ICE-HBV,  
South Africa

Professor Anna Kramvis, BSc Hons, PhD, is Research Professor and Director of the Hepatitis Virus Diversity Research Unit (HVDRU), a University-recognized research entity.

She is a Fellow of the Academy of Science of South Africa (ASSAf).

Professor Kramvis together with Professor Jake Liang of NIH organized the 2017 International HBV Meeting (<https://www.hbvmeeting.org/>) in Washington in September 2017 and has been asked to organize the 2023 International HBV Meeting, together with Professors Patrick Arbuthnot, Wits and Richard Njouom from Cameroon. It will be the first time, in its over 35 year history, that this meeting will be held on African soil.

She is a member of the European Association for the Study of the Liver (EASL) and sits on various international committees including the AIDS Clinical Trials Group (ACTG) Hepatitis Transformative Science Group, Governing Body of the International Committee to Eliminate HBV (ICE-HBV), Member of ICE-HBV Virology, Chronic Hepatitis B Management in Resource-Limited Settings working groups and convener of the Biomarkers Group. In October 2020 with Professor Peter Revill, she organized a virtual ICE-HBV Biomarkers Workshop (<https://ice-hbv.org/hbv-serum-biomarkers-workshop/>).

She is or has been on the editorial board of Annals of Hepatology, Frontiers, Virology Journal, Hepatology, PlosOne and Biomed Central Infectious Diseases.

She is a passionate advocate for the elimination of hepatitis in sub-Saharan Africa through increased vaccination coverage, especially of the birth dose; through diagnosis, to find the missing millions; and improved access to treatment for those eligible

**Potential conflict of interest**

No Information Received



## Organizing Committee

**Jeffrey V. Lazarus,**  
PhD, MIH, MA

Barcelona Institute for Global Health (ISGlobal), Spain

Jeffrey V. Lazarus (Ph.D., MIH, MA) holds positions as an associate research professor at the Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, where he leads the health systems research team, as Associate Professor at the Faculty of Medicine, University of Barcelona, Spain and as a senior scholar at the CUNY Graduate School of Public Health and Policy in New York City. His decade-long career as health systems, HIV, and viral hepatitis expert at WHO Europe was followed by three years (2009-2012) as a senior specialist at the Global Fund to Fight AIDS, Tuberculosis, and Malaria, three years as director of Health Systems Global (2012-15) then board chair of the foundation AFEW International (2015-18).

Prof Lazarus is now Vice-Chairman of the board of the EASL International Liver Foundation, where he developed the micro-elimination approach to HCV elimination. He is also a member of the INHSU international education committee and co-chair of the HIV Outcomes Beyond Viral Suppression coalition. He is the author of more than 300 publications and his current scientific work includes leading the Hep C Free Baleares, HBV COMSAVA, and Copenhagen T'n'T studies, and the Global COVID-19 consensus statement on ending the pandemic. He is a core member of The Lancet GastroHep Commission on Viral Hepatitis, a co-author of the Lancet COVID-19 commission and a commissioner of the EASL-Lancet European Liver Commission and The Lancet-IAPAC HIV Commission.

At AME/VE he is chair of the NAFLD models of care workshop, on the organizing committee of COLDA, and on the scientific committee of IVHEM.

Twitter: @JVLazarus

LinkedIn: Jeffrey V. Lazarus

### Potential conflict of interest

AbbVie, Gilead, Intercept, Janssen, MSD



## Organizing Committee

**Olufunmilayo Lesi,**  
MD, MBA, FMCP

World Health Organization, Switzerland

Dr. Olufunmilayo ('Funmi) Lesi currently leads the Hepatitis team in the Global HIV, Hepatitis and STI Programmes at the World Health Organization and coordinates hepatitis activities in collaboration with other WHO Departments to provide technical and strategic support for viral hepatitis elimination efforts in countries.

She is Professor of Medicine, College of Medicine, University of Lagos (CMUL), Nigeria and was previously Honorary Consultant and Head of Hepatology at the Lagos University Teaching Hospital where she established a liver disease care programme for Hepatitis B and C and liver cirrhosis and cancer. She was recently the regional advisor for viral hepatitis at the WHO Regional Office for Africa where she led the technical support for the development of national strategies and policies related to hepatitis epidemiology, prevention, and management in over 22 countries in sub-Saharan Africa and proactively contributed to enhancing the regional profile of viral hepatitis.

No potential conflict of interest to report



Organizing Committee  
**Casimir Manzenzo,**  
**MD, MPH**

World Health Organization,  
Gabon

Casimir MANZENGO MINGIEDI, is a Medical Doctor and Master of Public Health. He is bilingual, Congolese from DRC and living in Libreville for working reason.

He is working for WHO as Regional Hepatitis Advisor, Regional Office for Africa.

He has 26 years of Public Health experience, beginning by the peripheral level as Clinician in DRC, at the Sub-National level, National level and now at Regional level since 2018.

As Hepatitis Regional Officer, he is supporting Africa countries for advocacy, put on place Hepatitis program, Technical Assistance for Strategic Planning, Guidelines elaboration and training materials dissemination and program implementation follow-up.

Also, with his strong Public Health and HIV background, as one of pioneers of PMTCT implementation in DRC rural Health Zones, he is fully involved in the Triple elimination advocacy and Technical Assistance to the countries in partnership with all PMTCT actors, including the Organization of First Ladies in Africa for Development.

Potential conflict of interest

No Information Received



Invited Speaker  
**Yuyun S.**

**Maryuningsih,**  
**MD, PhD**

World Health Organization,  
Switzerland

Yuyun Siti Maryuningsih, Team Leader for Blood and other Products of Human Origin, Technical Standard and Specifications Unit, Health Products Policy and Standards Department, WHO Headquarter

Potential conflict of interest

No Information Received



**Invited Speaker**  
**Shevanthi Nayagam,**  
**MBBS, MRCP, PhD**  
Imperial College,  
United Kingdom

Dr. Shevanthi Nayagam is a Consultant Hepatologist and Clinical Academic at Imperial College London. Her research, to date, has focused on combining clinical field epidemiology, applied modelling and health economics in guiding public health policy towards the elimination of viral hepatitis, with a focus on low-and middle-income countries.

She is a research member of the PROLIFICA team (Prevention of Liver Disease and Cancer in Africa) and has worked with many countries to support their national hepatitis strategies. Since 2012 she has also worked with WHO in various advisory roles (including guidelines development) and is a member of the Vaccine Impact Modelling Consortium.

No potential conflict of interest to report



**Session Chair**  
**Gibril Ndow,**  
**MD**  
Clinical Research Fellow /  
Hepatitis Research Group  
Lead,  
The Gambia

Dr. Gibril Ndow is a Clinical Research Fellow at the MRC Unit The Gambia at LSHTM and an honorary research fellow at Imperial College London.

Dr. Ndow coordinate the PROLIFICA (Prevention of Liver Fibrosis and Cancer in Africa, [www.prolifica.africa](http://www.prolifica.africa)) research program in The Gambia and Senegal and lead several ancillary hepatitis B studies at the MRC Gambia.

Dr. Ndow's research investigates the mechanisms underlying disease progression and surface antigen loss in Africans with chronic hepatitis B infection, and aims to identify new biomarkers of disease severity and targets for curative treatment.

**Potential conflict of interest**

No Information Received



### Conference Chair

**Mark Nelson,**  
MA, MBBS, FRCP

Chelsea and Westminster  
Hospital / Imperial College  
Medical School,  
United Kingdom

Mark Nelson is a consultant physician at the Chelsea and Westminster Hospital, London. He trained at Jesus College, Cambridge and Westminster Hospital medical school from where he qualified in 1986. He was appointed Consultant Physician at this hospital in 1991 where he is presently the professor of HIV medicine at Imperial College Medical School where he is also the senior tutor. Since that time he has built a large HIV practice with a special interest in HIV in patient care, co-infection with hepatitis B and C and the clinical utility of new antiretroviral agents. He has published over 650 papers on HIV and hepatitis.

Professor Nelson has chaired the BHIVA guidelines committee for opportunistic infections and for hepatitis C. He is a member of the Guidelines Committee for Treatment, Malignancy and for HIV transmission. He was previously the chair of the BHIVA hepatitis special interest group and of the BHIVA science and education committee. He is a trustee of several charities associated with HIV. He has been awarded a visiting professorship at the Aga Khan Hospital, Nairobi, Kenya and most recently the certificate of merit by the government of Vietnam.

#### Potential conflict of interest

AbbVie, BMS, Hetero, Gilead, GSK, MSD, Mylan, ViiV



### Session Chair

**Ashraf Omar,**  
MD, MSc


Cairo University,  
Egypt

Professor Ashraf Omar Abdel Aziz is Professor of Hepatology & Tropical Medicine Faculty of medicine at Cairo University. He is a Liver Transplant Consultant Cairo University & Dar Al-Fouad Hospital and Chairman of the Egyptian Society of Liver Cancer (ESLC).

Additionally he also Director of the Multidisciplinary Liver Cancer Clinic Cairo University, Consultant hepatologist at the National Cancer Institute (NCI) in Cairo, Board editor of Hepatocellular carcinoma journal, Chairman of MENA NCCN committee of Hepatobiliary cancer, and a council member of IC-HEP.

#### Potential conflict of interest

No Information Received



## Invited Speaker

### **Janvier Serumondo, MD, MSc, MPH**

Rwanda Biomedical Centre,  
Rwanda

Dr Janvier is a Medical Doctor holding 2 Masters' degrees in Public Health and in Transfusion Medicine both from the University of Liege, Belgium. He has occupied Public Health leadership positions for more than 13 years in Rwanda Health Sector. Currently, Dr Janvier works at Rwanda Biomedical Centre and serves as the Director of Sexually Transmitted Infections and Other Blood Borne Infections Unit which also includes the Viral Hepatitis Management.

He has been the Director of Quality Assurance and Quality Control Unit in the Rwanda Biomedical Centre, National Reference Laboratory (NRL) for 6 years, with a vast experience in Laboratory Quality Management System and ISO Accreditation Standards.

Dr Janvier has also been Director for Blood Transfusion Services in Rwanda for 2 years and a half and acquired also an international experience in the area of Transfusion Medicine from Liege (Belgium) Blood Transfusion Centre.

Dr Janvier greatly contributed to the development of several National documents (strategic plans, policies, guidelines, Laboratory Quality Management System Documents) and the accreditation of NRL. He currently plays a key role in strengthening the National Viral Hepatitis Program towards hepatitis elimination. Finally, he also served as a University Lecturer. His research interests include Viral Hepatitis, Sexually Transmitted Infections, Laboratory, Transfusion Medicine and Public Health at large.

No potential conflict of interest to report



## Session Chair

### **Edford Sinkala, BScHB, MBChB, MMed, FCP (ECSA), PhD, FRCP (Edin)**

University of Zambia,  
Zambia

Edford Sinkala is a Consultant Physician, Hepatologist, and Lecturer at the University of Zambia, School of Medicine, Lusaka, Zambia.

He also serves as Head of Department of Internal Medicine at the University of Zambia, School of Medicine. He is the Head of Gastroenterology/ Hepatology unit at the University Teaching Hospital. He is one of the Directors of Tropical Gastroenterology and Nutrition Group (TROPGAN) which is a research group housed within the Department of Internal Medicine at the University of Zambia, School of Medicine.

His main research interests are around hepatosplenic schistosomiasis and hepatitis B virus (HBV), both of which are common in Zambia. He serves as Principal or Co-Investigator on several HBV studies in Zambia.

#### Potential conflict of interest

No Information Received



### Panelist

**Heidi Smuts,**  
BSc (Hons), PhD

Groote Schuur Hospital,  
South Africa

Heidi Smuts was a principal medical scientist, since retired, at the National Health Laboratory Service (Virology) at Groote Schuur Hospital. She was responsible for the diagnostic testing for HBV and HCV drug resistance mutations and genotyping in patients referred by the Liver Unit.

Her research interests include HCV and HBV phylogenetics/molecular biology and enteroviral infections, particularly aseptic meningitis outbreaks.

#### Potential conflict of interest

No Information Received



### Organizing Committee

**Mark Sonderup,**  
B Pharm, MBChB, FCP(SA),  
MMed

University of Cape Town,  
South Africa

Professor Mark Sonderup was born and schooled in the Eastern Cape. He obtained a B Pharm degree cum laude from the University of Port Elizabeth in 1990 and an MBChB cum laude from the University of Cape Town in 1995. His internship training was in Port Elizabeth at Livingstone Hospital and his postgraduate training was at the University of Cape Town and Groote Schuur Hospital where he obtained a Fellowship of the College of Physicians in 2002.

Between 2002 and 2004, he completed a 2 year fellowship in Hepatology at the UCT/MRC Liver Research Centre and Liver Clinic at Groote Schuur Hospital. He briefly worked in the UK before being appointed as a Senior Specialist in the Department of Medicine and Division of Hepatology at UCT and Groote Schuur Hospital in 2007.

He is currently Associate Professor in the Department of Medicine and Division of Hepatology. His research interests include HIV/AIDS associated liver disease, viral hepatitis, drug induced liver injuries and the porphyria's. His publications included peer reviewed articles, chapters and proceedings. He currently serves on the WHO Strategic Advisory Committee on Viral Hepatitis.

#### Potential conflict of interest

No Information Received



## Session Chair

**Elijah Songok,**  
MD, PhD

Kenya Medical Research  
Institute,  
Kenya

Elijah Martim Songok is a professor and Chief Research Officer at Kenya Medical Research Institute in Nairobi, Kenya. Apart from his position at KEMRI he is also cross appointed as Professor at Department of viral Infections and International Health at Kanazawa University, Japan and Department of Medical Microbiology, University of Manitoba, Canada.

Prof. Songok obtained his BSc and MSc degrees in Biochemistry from the University of Nairobi, a PhD in viral infections from Kanazawa University in Japan and a postdoctoral fellowship from University of Manitoba in Canada.

In Kenya, he has been the Head of KEMRI Infectious and Parasitic Diseases Research Program; Chair of the Kenya World Hepatitis Day Commemoration Committee and a Technical expert for development of Kenya National Guidelines for diagnosis, treatment and prevention of viral hepatitis. He is also a member of WHO-UNAIDS network for HIV isolation and characterization, and an expert committee member of the Kenya Advisory Committee for Blood Safety and Availability.

Prof. Songok has published more than 50 articles in peer reviewed journals and won grants and awards from major international and local grant agencies for research and capacity building in viral infections. These include Bill and Melinda Gates Foundations, Japan International Cooperation Agency (JICA), Canada Institutes of Health Research (CIHR), Canada International Development Research Centre (IDRC), Third World Academy of Sciences, Toyota Foundation among others.

Prof. Songok is currently a Deputy Director of Kenya Medical Research Institute in charge of the KEMRI Graduate School.

### Potential conflict of interest

No Information Received



## Local Chair

**Wendy Spearman,**  
MBChB, FCP, FRCP, MMed,  
PhD

University of Cape Town,  
South Africa

Wendy Spearman is Head of the Division of Hepatology, Department of Medicine, Faculty of Health Sciences at the University of Cape Town. She is Head of the Liver and Liver Transplant clinics at Groote Schuur Hospital.

She completed her 2-year Hepatology Fellowship under Professors Ralph Kirsch and Simon Robson at the UCT/MRC Liver Research Centre in 1991 and obtained her PhD in 2008 from the University of Cape Town on "The effect of two novel C-type lectins, Ba100 and Ba25, isolated from the venom of the puff adder, Bitis arietans on T lymphocyte proliferative responses." She is actively involved in outreach Liver education programmes, was appointed by the International Association of Providers of AIDS Care to develop Training modules on the management of Hepatitis B for sub-Saharan Africa and is co-director of the Viral Hepatitis in sub-Saharan Africa ECHO clinic.

She was appointed as the lead consultant for the National Guidelines on the management and prevention of viral hepatitis in South Africa. Her research interests include viral hepatitis, drug-induced liver injuries, liver transplantation and novel immunosuppressants.

### Potential conflict of interest

Gilead Sciences, Roche Diagnostics (Pty) Ltd





## Organizing Committee

### **John Ward, MD**

Coalition for Global Hepatitis Elimination, Task Force for Global Health / Rollins School of Public Health, Emory University, United States

Dr. John W. Ward created and directs the Coalition for Global Hepatitis Elimination of the Task Force for Global Health. The Coalition is a community of practice providing technical assistance and monitoring progress toward hepatitis elimination in over 190 countries.

Dr. Ward is an advisor to WHO Geneva, WPRO, PAHO, and the African Union. Dr. Ward chairs the AASLD Task Force for Hepatitis Elimination.

Over a 13-year tenure, Dr. Ward directed the US CDC Division of Viral Hepatitis with responsibilities for viral hepatitis surveillance, prevention, and research. At the national level, Dr. Ward developed recommendations for hepatitis A and hepatitis B vaccination, hepatitis B and hepatitis C screening, and authored the first national action plan to prevent viral hepatitis. Dr. Ward guided the launch of pioneer HCV elimination programs.

Previously, Dr. Ward led US HIV/AIDS surveillance and served as Editor of the CDC MMWR and of Silent Victories, a history of public health in the 20th century.

Dr. Ward has authored over 150 scientific publications. He received his medical training at the University of Alabama at Birmingham and University of Washington, Seattle. Dr. Ward is a Professor in the Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta.

#### Potential conflict of interest

No Information Received

# Acknowledgment

## Corporate Support

### GOLD LEVEL SPONSORS



### PRINCIPAL SUPPORTER



### SUPPORTER LEVEL SPONSOR



### CONTRIBUTOR LEVEL SPONSOR



### FRIEND LEVEL SPONSOR



### ENDORSERS



# CREATING POSSIBLE

We are committed to a better, healthier world for everyone



ZA-UNB-0028



 **GILEAD**  
Creating Possible



## A NEW LEVEL OF SENSITIVITY DETERMINE™ HBsAg 2

Rapid, Accurate Hepatitis B Virus (HBV) Screening in Many Healthcare Settings



### LEAVE NO PATIENTS BEHIND



Determine™ HBsAg 2, with an analytical sensitivity of just 0.1 IU/mL, is a **highly sensitive, easy-to-use** rapid lateral flow test



Enables accurate identification of HBsAg-positive patients with results in **just 15 minutes**



Detects major HBsAg vaccine **escape mutants**



Ideal for use in a **wide variety of** healthcare settings

PRODUCT MAY NOT BE AVAILABLE IN ALL MARKETS AND IS SUBJECT TO REGULATORY APPROVAL IN REGULATED COUNTRIES.  
© 2021, Abbott. All rights reserved. All trademarks referenced are trademarks of either the Abbott group of companies or their respective owners.  
Any photos displayed are for illustrative purposes only. Any person depicted in such photos is a model. COL-2019-01-09-21

The background features a large, abstract geometric design. A bright red shape, resembling a triangle or a large 'V', is positioned in the upper left and center. The rest of the background is a gradient of green, transitioning from a lighter shade near the red shape to a darker shade at the bottom.

**ame**

**academic  
medical education**

[AcademicMedicalEducation.com](http://AcademicMedicalEducation.com)